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Abstract
Nod-like receptors (NLRs) are important innate pattern recognition receptors and regulators
of inflammation or play a role during development. We systematically analysed 41 non-syn-
onymous single nucleotide polymorphisms (SNPs) in 21 NLR genes in a Czech discovery
cohort of sporadic colorectal cancer (CRC) (1237 cases, 787 controls) for their association
with CRC risk and survival. Five SNPs were found to be associated with CRC risk and eight
with survival at 5% significance level. In a replication analysis using data of two large
genome-wide association studies (GWASs) from Germany (DACHS: 1798 cases and 1810
controls) and Scotland (2210 cases and 9350 controls) the associations found in the Czech
discovery set were not confirmed. However, expression analysis in human gut-related tis-
sues and immune cells revealed that the NLRs associated with CRC risk or survival in the
discovery set were expressed in primary human colon or rectum cells, CRC tissue and/or
cell lines, providing preliminary evidence for a potential involvement of NLRs in general in
CRC development and/or progression. Most interesting was the finding that the enigmatic
development-related NLRP5 (also known as MATER) was not expressed in normal colon
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tissue but in colon cancer tissue and cell lines. Future studies may show whether regulatory
variants instead of coding variants might affect the expression of NLRs and contribute to
CRC risk and survival.
Introduction
Within the last few years it has become evident that the interplay between pattern recognition
receptors (PRRs), such as Toll-like receptors (TLRs) or Nod-like receptors (NLRs), and the gut
microbiota has a profound influence on the homeostasis of the immune system and therefore
on many important aspects of human health [1–3]. If undisturbed and well-regulated, this
symbiosis is beneficial for the human host. A disruption of the underlying regulatory pathways
can, however, result in the development of local and chronic inflammation, inflammatory
bowel disease (IBD) and/or colorectal cancer (CRC) [4, 5]. Gut homeostasis is maintained by a
physical separation of the microbial community from the gut epithelia by the mucosa and a
mucus layer. PRRs monitor the integrity of this barrier and the adjacent microbial community
by detecting microbe-associated molecular patterns (MAMPs) as well as endogenous damage
associated molecular patterns (DAMPs), and consequently controlling antimicrobial responses
that contribute to an equilibrium between microbes and host [2, 4–6]. The activation of PRRs
TLRs and/or NLRs by MAMPs or DAMPs results in the activation of multiple signaling path-
ways including nuclear factor-κB (NF-κB), mitogen-activated protein kinases (MAPKs), and
the type I interferon (IFN) response, with subsequent induction of an inflammatory and anti-
microbial response that includes secretory IgA, antimicrobial peptides, pyroptosis and autop-
hagy [1, 2, 7]. Some NLRs, such as NLRP1, 3, 6, 12 and NLRC4, form so-called “inflamma-
some” complexes, comprising of the respective NLRs, the adaptor Apoptosis-associated speck-
like protein containing a CARD (ASC) and pro-caspase-1. Inflammasome assembly initiates
inflammatory and antimicrobial response via the autoproteolytic cleavage of caspase-1, catalys-
ing the proteolytic conversion of pro-interleukin-1β (IL-1ß) and other IL-1 family members
into biologically active cytokines which drive inflammation [2, 8, 9].
We recently reported an impact of TLR polymorphisms on CRC survival [10, 11]. Given
the suggested concerted action of TLR and NLR signaling [1, 2], the connection between NLRs
and CRC seemed of special interest. Provoking studies in mice and association studies in
humans have suggested that NLR signaling is involved in inflammatory bowel disease, chronic
inflammation and gastrointestinal cancers, including CRC [6, 11, 12]. Apart from various
reports on mice, convincing data directly connecting NLRs and human CRC are available only
for NOD1, NOD2 and NLPR3, which were found to be associated with susceptibility, progres-
sion and treatment of sporadic CRC, colitis and/or colitis-associated CRC [13, 14]. In general,
it is unclear whether and how other NLRs contribute to human CRC development or progres-
sion. Additionally, the functional importance of NLRs that have embryonic lethal phenotypes
in mice–so-called “reproduction-related NLRs” like NLRP2, 5 and 13 –in human immunity
and/or tumorigenesis remains an unresolved question [8].
In order to systematically investigate the influence of potentially functional coding poly-
morphisms in the NLR genes on sporadic CRC risk and survival, we conducted a case-control
study with replications in 2 large genome-wide association studies (GWASs), covering the
majority of known non-synonymous single nucleotide polymorphisms (nsSNPs) in 21 genes
across different NLR signalling pathways. In silico analysis was done on selected nsSNPs in the
NLR gene family. Furthermore, RNA expression of selected genes was measured to assess
mRNA expression in immune cells, biopsies and/or CRC cell lines.
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Methods and material
Ethical approval
The Czech study: Ethics Committee of the Institute of Experimental Medicine, Academy of
Sciences of the Czech Republic, 26.3.2004; Ethics Committee of the Institute of Clinical and
Experimental Medicine and Faculty Thomayer Hospital, Prague, Czech Republic, 29.4.2009;
and Ethics Committee of the General University Hospital, Prague, Czech Republic, 4.4.2011.
For the work in Tübingen: All patients or healthy blood donors included in gene expression
analyses for this study provided their written informed consent before study inclusion.
Approval for use of their biomaterials was obtained by the local ethics committee at the Uni-
versity of Tübingen, in accordance with the principles laid down in the Declaration of Hel-
sinki. Terminal ileum/ colon biopsies were obtained from patients undergoing routine
colonoscopy at the University Hospital Tübingen, buffy coats obtained from blood donations
of healthy donors were received from the Center for Clinical Transfusion Medicine (ZKT) at
the University Hospital Tübingen and whole blood from voluntary healthy donors was
obtained at the University of Tübingen, Department of Immunology.
The DACHS study was approved by the ethics committee of the Medical Faculty of the Uni-
versity of Heidelberg (no. 310/2001). The DACHS study is registered: StudyBox no. ST-066,
DRKS no. DRKS00011793
The work in Scotland was approved by the UK National Health Service Research Ethics
Committee (approval references 13/SS/0248; 11/SS/0109 and 01/0/05).
SNP selection and in silico analysis of conservation and functional
relevance
21 candidate NLR genes (NLRP1-14, NLRC4 and 5, NOD1 and 2, NAIP, RIPK2 and ASC
[PYCARD]) were screened for non-synonymous variants. Thirteen of the 21 genes harboured
validated missense variants with a minor allele frequency (MAF) > 0.01 in the CEU reference
panels (Source: 1000Genomes, HapMap, dbSNP). Choosing only one SNP per linkage block
(r20.8), 41 SNPs were selected for genotyping (Table A in S2 File & Fig 1).
To gain additional insight into a possible functional relevance, all genotyped and linked
SNPs were mapped to their location in the respective proteins. 19 of the 41 genotyped SNPs are
located in defined NLR protein domains [3] (Fig 1 & Table A in S2 File): 11 in the NACHT
domain, seven in the LRR domain and one in the PYD domain. The remaining genotyped
SNPs mapped to linker regions. SIFT (sift.jcvi.org) and PolyPhen2 (genetics.bwh.harvard.edu/
pph2) databases were used to assess possible effects of the SNPs on the protein. 23 of the geno-
typed SNPs are predicted to be deleterious or damaging, and/or to result in non-sense mediated
decay or retained introns (Fig 1 & Table A in S2 File). Assessments of evolutionary conservation
of the selected variants was performed by three software suites namely Genomic Evolutionary
Rate Profiling (GERP [15]), PhastCons [16] and phylogenetic p-value (PhyloP [17]). The GERP
score of>2.0 and the PhastCons score (values between 0–1) of>0.3 indicate a good level of
conservation of the variants. Positive PhyloP scores (values between −14 and +6) are predicted
to be conserved. Higher values of these tools reflect the probability that the nucleotide is located
at a conserved position, based on the multiple alignment of genome sequences of 100 different
vertebrates. Lower values of these tools reflect fast-evolving variant positions.
Discovery set—Czech Republic
Study population. The study was carried out on a Czech CRC case-control population of
patients (n = 1237; median age 63 years; 61.7% males) with colon or rectal malignancy—
NOD-like receptors in CRC
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excluding hereditary-nonpolyposis colorectal cancer (HNPCC)—and healthy blood donors
(n = 787; median age 47 years, 55.4% males, all cancer-free at the time of sampling), (Table B
in S2 File.) [18]. For overall survival (OS) 477 incident CRC cases with information about age,
sex, TNM staging, tumor grade, date of death or end of follow-up (August 31, 2011; median
follow-up 58 months) were available. For event-free survival (EFS) in patients with non-meta-
static disease at the time of diagnosis (n = 325), date of distant metastasis, tumor recurrence,
death, or end of follow-up was used as the study end point (median follow-up 55 months).
Fig 1. Protein structure of the candidate genes with genotyped SNPs (open and filled star symbols ☆/$), and all linked
missense SNPs (triangle4; r2 0.8). Filled star ($) and triangle (▲): SNPs predicted damaging (SIFT) or deleterious
(Polyphen).
https://doi.org/10.1371/journal.pone.0199350.g001
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SNP genotyping. TaqMan SNP Genotyping Assays (Applied Biosystems) or KASP geno-
typing assays (LGC Genomics) were used for the analysis of the SNPs. Case and control sam-
ples were amplified simultaneously in 384 well format (Hydrocycler 16 (LGC Genomics),
using 3 ng whole genome amplified DNA from blood). Endpoint genotype detection was car-
ried out on the ViiA 7 Real-Time PCR System (Applied Biosystems). Call rates for 40 out of 41
SNPs were 94–99%. Internal quality controls showed a concordance rate of 99%. Samples
with< 50% call rate over all assays were excluded from the study.
Replication sets—Germany and Scotland
For replication, all SNPs associated with CRC in the Czech population (p<0.05) were tested in
two large European genome-wide association studies (GWASs) carried out in Germany
(„Darmkrebs: Chancen der Verhütung durch Screening Study”–DACHS) [19, 20] and in Scot-
land (Table B in S2 File) [21, 22].
Germany. The sample set used as the replication set is part of the still on-going DACHS
project and comprised 1796 CRC patients (median age 69 years; 58.6% males) who received
in-patient treatment due to a first diagnosis of CRC in 22 hospitals of the Rhine-Neckar-Oden-
wald region of Germany. The 1810 community-based controls were randomly selected from
population registries matched for gender, 5-year age groups and county of residence (median
age 70 years, 59.6% males, cancer-free at the time of sampling), (Table B in in S2 File) [19, 20].
Cases and controls genotyped in the present study were recruited between January 01, 2003
and December 31, 2007. For overall survival (OS) analysis, 1794 incident CRC cases with infor-
mation about age, sex, tumor stage, and a median follow-up time of 48.4 months in men and
49.9 months in women were available [23].
Cases and controls were genotyped on the Illumina HumanCytoSNP or Illumina HumanOm-
niExpress platform [24]. Imputation was performed for autosomal SNPs to the CEU population in
HapMap II release 24 using MACH (available at: www.sph.umich.edu/csg/abecasis/MACH/tour/)
[24] with MAF (<0.01) and imputation accuracy (R2< 0.3) excluded from the analysis [25].
Scotland. The Scottish study series comprised 2115 cases (median age 57 years, 57%
males) from the Scottish colorectal cancer study (SOCCS) [21] and 95 cases (median age 67
years, 66% males) from Ninewells Hospital, Dundee and Perth Royal Infirmary collected
between 1997 and 2000 [26]. SOCCS is a case-control study designed to identify genetic and
environmental factors associated with non-hereditary CRC risk and survival outcome. Popula-
tion controls with no personal history of cancer were ascertained from four cohorts including
8533 (42% males, mean age 55.4 yrs)—from Generation Scotland-Scottish Family Health
Study [27, 28]; 513 (41% males, mean age 79 years) and 1004 (50.6% males, mean age 70 years)
from the Lothian Birth Cohorts 1921 and 1936, respectively; and 262 Dundee controls (50%
males) were recruited through the same General Practice surgeries as cases or from spouses/
friends of cases [29]. The detailed information on genotyping cases and controls and data qual-
ity control is described elsewhere [22]. 2210 cases and 9350 controls were included in the final
analysis. The survival analysis was performed in a subset of SOCCS study comprising 1402
patients (median follow up 107 months, recruited between 2001 and 2006) with colorectal ade-
nocarcinoma confirmed by pathological assessment. Participants completed a detailed lifestyle
questionnaire and a semi-quantitative food frequency and supplements questionnaire (http://
www.foodfrequency.org). Genotyping was performed using the Infinium Human Exome
BeadChip 12v1.0 or 12v1.1 (Illumina), with genotype calling using Illumina GenCall for
HumanExome-12v1.0 and HumanExome-12v1.1 versions called separately. Generation Scot-
land controls and a subset of the cases from the SOCCS study were genotyped using OmniEx-
pressExome BeadChip 8v1.1 or 8v1.2 (Illumina).
NOD-like receptors in CRC
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In accordance with the Declaration of Helsinki, all participants provided written informed
consent. The studies were approved by the local ethics committees.
Statistical analysis—Discovery set
Genotype frequencies in controls were tested for Hardy-Weinberg equilibrium (HWE; Pear-
son’s goodness-of-fit χ2 test, deviation assumed at p< 0.001). NLRP11 rs12461110 was
excluded for violation of HWE.
Single variant associations with CRC risk, overall and event-free survival. Odds ratios
(ORs) and 95% confidence intervals (CIs) for associations between genotypes and CRC risk
were estimated by logistic regression (PROC LOGISTIC, SAS V9.3; SAS Institute, Cary, NC)
and refer to the minor allele. P values were considered nominally significant at p0.05, with a
study-wide significance level at p0.001 considering Bonferroni correction for multiple test-
ing (0.05/39 = 0.0012). ORs were adjusted for age and sex. The estimated power was> 95% for
OR1.5 (MAF > 5%; p = 0.05; dominant model) [30].
Differences in OS and EFS between genotypes were estimated by hazard ratios (HRs) and
95% CIs using Cox regression (PROC PHREG, SAS V9.3) adjusting for age, sex, tumor grade
and tumor stage. The estimated power was > 90% for HR 2.0 (MAF > 10%, p = 0.05). OS
was calculated for all patients (OS(pM0&1)); for patients with non-metastatic disease at the time
of diagnosis OS (OS(pM0)) and EFS (EFS(pM0)) were calculated. Kaplan-Meier plots were gener-
ated, estimating the differences between the survival functions by log-rank test (PROC LIFET-
EST, SAS V9.3).
Additive SNP associations with CRC risk and survival. Additive influence of the risk
alleles (p0.05) on CRC risk and survival identified in the Czech population was estimated
(risk: five SNPs, 0–10 risk alleles per individual; survival: eight SNPs, 0–16 risk alleles). For
each SNP the allele associated with a higher OR or HR was designated the “risk allele”. Patients
were grouped into equally sized groups of risk alleles (risk: 0-3/4-5/6-10; survival: 0-5/6-7/8-
12) and ORs and HRs were calculated, adjusting for age and sex, HRs also for tumor grade and
stage. Kaplan-Meier plots were generated for the additive survival model and the log-rank test
was performed. The same analysis was conducted separately for the three NLRP5 risk SNPs
(p0.05) (0–6 risk alleles).
Statistical analysis—Replication sets. Data provided by the DACHS study consisted
mostly of imputed genotypes, all in dosage format referring to the number of copies of minor
allele. To permit direct comparison with the German data set genotype data from the Czech
study was coded as 0, 1, or 2 copies of the minor allele. For these two data sets, association
between SNPs and risk for CRC was obtained by applying logistic regression considering a
log-additive genetic effect model (PROC LOGISTIC, SAS Version 9.2; SAS Institute). HRs
(PROC PHREG, SAS version 9.2, SAS Institute) were calculated via Cox regression with a
model that included the SNP coded as number of copies of the minor allele, age, sex and
tumor stage for both sample sets.
ORs and 95% CIs for association between each of the genotypes and risk of CRC in Scot-
land were estimated using unconditional logistic regression adjusted for age and gender. HRs
and corresponding 95%CI for overall survival analysis in Scotland was calculated for each of
the genotyped SNPs and dominant model using Cox regression adjusted for age, gender and
TNM stage. OS was calculated for all patients (OS(pM0&1)) and for patients with non-metastatic
disease at the time of diagnosis OS (OS(pM0)). No event-free survival analysis was performed in
the Scottish data. All analysis was performed in R v3.1.0 (R Development Core Team. R: A
Language and Environment for Statistical Computing. Vienna: R Foundation for Statistical
Computing, 2014).
NOD-like receptors in CRC
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Gene expression
For expression analyses, patients providing biopsy material were recruited at the University
Hospital Tübingen. Healthy blood donors were recruited at the Center for Clinical Transfu-
sion Medicine (ZKT), University Hospital Tübingen and respective buffy coats obtained from
blood donations. All patients/ healthy blood donors included in gene expression analyses for
this study provided their written informed consent before study inclusion. Approval for use of
their biomaterials was obtained by the local ethics committee at the University of Tübingen, in
accordance with the principles laid down in the Declaration of Helsinki. Terminal ileum/
colon biopsies were obtained from patients undergoing routine colonoscopy at the University
Hospital Tübingen, buffy coats obtained from blood donations of healthy donors were
received from the Center for Clinical Transfusion Medicine (ZKT) at the University Hospital
Tübingen and whole blood from voluntary healthy donors was obtained at the University of
Tübingen, Department of Immunology.
Cell lines, primary human immune cells and biopsy material. HCT116, DLD-1 and
Caco2 cells were grown and sourced as described [31], without re-authentication. Primary leu-
kocytes were isolated from buffy coats (Tübingen University Hospital, Center for Clinical
Transfusion Medicine (ZKT)) using Ficoll (GE Healthcare) density gradient purification and
CD14+ monocytes were isolated using MACS (Miltenyi) magnetic beads to a purity of> 95%
(anti-CD14-PE flow cytometry, BD). Subsequently, cells were differentiated into monocyte-
derived dendritic cells (MoDC) or monocyte-derived macrophages (MoMacs) by culture in
RPMI 1640 medium (Invitrogen) supplemented with 10% fetal calf serum (FCS) in the pres-
ence of 40 ng/ml IL-4 and 25 ng/ml GM-CSF (Peprotech) or with 25 ng/ml GM-CSF for 6
days, respectively. Neutrophils were isolated from the Ficoll pellet after NH4Cl lysis of erythro-
cytes. All cells were grown at 37˚C and 5% CO2. Biopsies from the terminal ileum or colon
(n = 12; median age 46; 56% males) were obtained during routine colonoscopy at the Univer-
sity Hospital Tübingen and stored in liquid nitrogen until analysis [13].
Gene expression analysis. Gene expression analysis was carried out using single-gene
TaqMan1 Gene Expression Assays (Applied Biosystems) for NLRP2, NLRP3, NLRP5, NLRP6,
NLRP13 and NLRC5. mRNA was isolated from whole blood or primary blood cells (two
donors, #1 and #2, respectively) or THP-1, HCT116, DLD-1 or CaCo2 cell lines using an
RNeasy Mini Kit (Qiagen) and commercially available RNA samples for human ovary, duode-
num, ileum (sample #7), rectum and colon adenocarcinoma were used (Agilent). RNA from
ileum or colon biopsies from six patients (samples #1–6) was isolated using TRIzol Reagent
(Life Technologies) according to standard protocols and reverse transcribed into cDNA using
oligo(dT)12 primer [13]. Following transcription to cDNA (High Capacity RNA-to-cDNA
Kit; Life Technologies), expression was analysed using pre-validated TaqMan1 Gene Expres-
sion Assays (Applied Biosystems). Data were normalized to TBP (TATA box binding protein).
The samples were analysed in triplicate using the 7500fast Real-Time System (Applied
Biosystems).
Results
NLR variants are associated with CRC risk and survival in the Czech
sample set
Nominally significant associations with CRC risk were detected for six SNPs (Table 1; Table C
in in S2 File). In an additive risk model combining those six variants, CRC risk increased sig-
nificantly with increasing numbers of risk alleles, and a maximum for carriers of 6–10 risk
alleles (OR 2.10, p = 0.0005; Table 1).
NOD-like receptors in CRC
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Eight SNPs were associated with altered OS and/or EFS (p0.05); Table 2; Table C in in S2
File). Strikingly, among them three unlinked SNPs in NLRP5 (r2 < 0.5) were associated with
decreased OS(pM0) and EFS(pM0). The additive survival model showed a nominally significantly
decreased OS and EFS with an increasing number of risk alleles (Table 2). The maximum effect
was detected for carriers of 8–12 risk alleles (HROS(pM0&1) 1.88, p = 0.003; HROS(pM0) 2.89
p = 0.0008 and HREFS(pM0) 3.02, p = 0.0003, respectively; Table 2).
GWAS data on the NLRP risk and survival SNPs—Replication sets
In order to validate the results from the Czech cohort, all SNPs included into the additive
model for CRC risk (N = 5) and survival (N = 8) were analyzed in two large GWAS sample
sets from Germany and Scotland. Complete data was available from the DACHS GWAS.
The Scottish GWAS provided data on three CRC risk variants (rs12150220, rs306457 and
rs303997) and seven survival variants (Table E in in S2 File). Scottish data was available for
Table 1. CRC risk: genotype distribution of SNPs analyzed in the Czech case-control population for SNPs with p 0.05. Amino acid changes are given as<> with
the amino acid position indicated. Data adjusted for age at diagnosis and sex. Nominal significance at p0.05; significance level corrected for multiple testing (39 geno-
typed SNPs) at p0.001.
Gene Risk of CRC
SNP Genotype Cases Controls OR (95%CI) P Val
NLRP2 C/C 427 284 1
rs1043673 A/C 574 355 1.08 (0.84–1.39) 0.56
1052: A<>E A/A 203 108 1.41 (1.00–1.99) 0.05
A/C + A/A 777 463 1.16 (0.91–1.47) 0.23
NLRP3 C/C 1114 700 1
rs35829419 A/C 85 66 0.63 (0.41–0.97) 0.04
705: Q<>K A/A 4 1 0.97 (0.09–10.11) 0.98
C/A + A/A 89 67 0.64 (0.42–0.98) 0.04
NLRP6 G/G 924 629 1
rs6421985 T/G 252 128 1.36 (1.01–1.83) 0.04
163: L<>M T/T - - - -
T/G + T/T 252 128 1.36 (1.01–1.83) 0.04
NLRP8 G/G 732 493 1
rs306457 C/G 415 235 1.13 (0.88–1.45) 0.32
1049: STOP<>Y C/C 63 26 2.01 (1.09–3.72) 0.03
C/G + C/C 478 261 1.20 (0.95–1.53) 0.13
NLRP11 A/A 1070 662 1
rs299163 A/C 134 91 0.94 (0.66–1.34) 0.74
188: A<>S C/C 7 12 0.21 (0.06–0.68) 0.01
A/C + C/C 141 103 0.83 (0.59–1.17) 0.2954
NLRP13 C/C 419 297 1
rs303997 C/T 564 334 1.37 (1.06–1.77) 0.02
247: R<>Q T/T 212 125 1.54 (1.10–2.16) 0.01
C/T + T/T 776 459 1.42 (1.11–1.80) 0.005
No. of 0–3 302 (27.83) 216 (32.34) 1 -
risk alleles a 4–5 633 (58.34) 381 (57.04) 1.36 (1.04–1.79) 0.03
6–10 150 (13.82) 71 (10.63) 2.10 (1.38–3.20) 0.0005
a NLRP11 rs299163 was excluded from the “No. of risk alleles analysis” due to low MAF 0.05: only the rare homozygote genotype was associated with CRC risk, not
contributing in risk in the Risk-SNP-Panel.
https://doi.org/10.1371/journal.pone.0199350.t001
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Table 2. Overall survival pM0&1 and pM0, and event-free survival pM0: genotype distribution of SNPs analyzed in the Czech case-control population for SNPs
with p 0.05. Amino acid changes are given as<> with the amino acid position indicated. Data adjusted for age at diagnosis and sex, tumor grade and tumor stage.
Nominal significance at p 0.05; significance level corrected for multiple testing at p 0.001.
Gene Overall Survival (pM = 0&1) Overall Survival (pM = 0) Event-free Survival (pM = 0)
SNP Genotype Cases Death (%) HR (95%CI) p-val Cases Deaths (%) HR (95%CI) p-val Cases Events (%) HR (95%CI) p-val
NLRP1 A/A 106 46 (43.40) 1 74 24 (32.43) 1 74 29 (39.19) 1
rs12150220 A/T 177 86 (48.59) 1.14 (0.79–
1.63)
0.49 130 43 (33.08) 1.10 (0.67–
1.83)
0.70 130 50 (38.46) 0.95 (0.60–
1.51)
0.81
155: H<>L T/T 78 42 (53.85) 1.57 (1.03–
2.40)
0.04 59 25 (42.37) 1.52 (0.86–
2.68)







0.2 189 68 (35.98) 1.23 (0.77–
1.97)
0.39 189 77 (40.74) 1.05 (0.68–
1.62)
0.82
NLRP2 C/C 125 73 (58.40) 1 87 38 (43.68) 1 87 42 (48.28) 1
rs1043673 A/C 181 71 (39.23) 0.64 (0.46–
0.89)
0.008 136 38 (27.94) 0.59 (0.37–
0.92)
0.02 136 45 (33.09) 0.61 (0.40–
0.93)
0.02
1052: A<>E A/A 56 30 (53.57) 0.83 (0.54–
1.28)
0.4 40 15 (37.50) 0.77 (0.42–
1.42)
0.41 40 16 (40.00) 0.75 (0.42–
1.35)
0.34




0.02 176 53 (30.11) 0.63 (0.41–
0.96)
0.03 87 42 (48.28) 0.64 (0.43–
0.96)
0.03
NLRP5 G/G 197 88 (44.67) 1 143 42 (29.37) 1 143 48 (33.57) 1
rs10409555 A/G 140 68 (48.57) 1.20 (0.87–
1.64)
0.3 104 39 (37.50) 1.53 (0.98–
2.38)
0.06 104 47 (45.19) 1.56 (1.04–
2.35)
0.03
1181: V<>I A/A 25 18 (72.00) 1.58 (0.93–
2.69)
0.09 17 10 (58.82) 3.04 (1.48–
6.23)





165 86 (52.12) 1.26 (0.93–
1.70)
0.13 121 49 (40.50) 1.69 (1.11–
2.58)
0.02 121 57 (47.11) 1.66 (1.12–
2.45)
0.01
NLRP5 C/C 268 122
(45.52)
1 195 61 (31.28) 1 195 69 (35.38) 1
rs12462795 C/G 90 47 (52.22) 1.28 (0.91–
1.81)
0.15 68 28 (41.18) 1.71 (1.07–
2.74)
0.03 68 34 (50.00) 1.80 (1.17–
2.76)
0.007
1108: S<>C G/G 6 5 (83.33) 2.79 (1.13–
6.90)
0.03 3 2 (66.67) 3.05 (0.73–
12.74)





96 52 (54.17) 1.36 (0.97–
1.89)
0.07 71 30 (42.25) 1.77 (1.12–
2.81)
0.02 71 36 (50.70) 1.84 (1.21–
2.79)
0.005
NLRP5 T/T 253 118
(46.64)
1 184 57 (30.98) 1 184 64 (34.78) 1
rs16986899 C/T 99 54 (54.55) 1.21 (0.87–
1.67)
0.26 73 33 (45.21) 1.70 (1.10–
2.64)
0.02 73 39 (53.42) 1.74 (1.17–
2.61)
0.007
912: M<>T C/C 8 2 (25.00) 0.27 (0.07–
1.13)
0.07 4 0 (0.00) 0.00 (0.00-.) 0.98 4 0 (0.00) 0.00 (0.00-.) 0.98
C/T + C/C 107 56 (52.34) 1.08 (0.78–
1.49)
0.64 77 33 (42.86) 1.58 (1.02–
2.44)
0.04 77 39 (50.65) 1.61 (1.08–
2.40)
0.02
NLRP12 C/C 225 112
(49.78)
1 161 60 (37.27) 1 161 71 (44.10) 1
rs34436714 A/C 113 50 (44.25) 0.93 (0.66–
1.30)
0.67 83 23 (27.71) 0.72 (0.45–
1.17)
0.19 83 26 (31.33) 0.67 (0.43–
1.06)
0.09
42: K<>N A/A 16 6 (37.50) 0.76 (0.33–
1.73)
0.51 13 3 (23.08) 0.51 (0.16–
1.65)
0.26 13 3 (23.08) 0.47 (0.15–
1.49)
0.2
A/C + A/A 129 56 (43.41) 0.91 (0.65–
1.26)
0.55 96 26 (27.08) 0.69 (0.43–
1.10)
0.12 96 29 (30.21) 0.64 (0.42–
0.99)
0.05
NLRC5 C/C 192 101
(52.60)
1 133 53 (39.85) 1 133 61 (45.86) 1
rs289723 A/C 149 65 (43.62) 0.87 (0.64–
1.20)
0.4 113 33 (29.20) 0.72 (0.46–
1.11)
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genotypes, DACHS data according to allelic probabilities. Despite the promising initial results,
neither the associations for CRC risk nor the associations for CRC survival were replicated in
the GWAS sets. We also tested the additive models in the DACHS population, but no associa-
tion was evident (data not shown).
Divergent expression patterns of NLRP2, 5, 6 and 13 in hematopoietic and
non-hematopoietic cells
To investigate whether the NLRs found to be associated with CRC in the Czech discovery set,
were expressed in the gut or immune cells, mRNA levels were quantified for selected NLRs in
primary tissue samples and cell lines. In gut-related tissues, CRC cell lines, whole blood and neu-
trophils (PMN), NLRP2 showed moderate expression, with the lowest expression in rectum (Fig
2A and 2B). Although NLRP2 showed low expression in CD14+ monocytes, this was increased
up to 100-fold in monocyte-derived primary dendritic cells and macrophages (Fig 2B). NLRP5
(also known as MATER) was not detectable in immune cells (not shown) and normal gut tissue
but in ovary (Fig 2C), in keeping with its role in oogenesis [8]. However, we observed expression
in a primary CRC sample and three CRC cell lines (Fig 2C) but not fibroblast or B lymphocyte
cell lines (not shown), in agreement with mRNA expression data from the GENT database
(Figure A in S1 File). Consistently with an earlier report [32], NLRP6 (also known as PYPAF5)
was highly expressed in neutrophils (PMN), low in monocytes and MoDC but not detectable in
gut biopsies (not shown). NLRP13 was below the level of detection in all analysed samples except
for the positive control, ovary and the DLD1 CRC cell line (Fig 2D). NLRC5 was expressed to
varying degrees in healthy gut tissue and most highly in colon adenocarcinoma, and was induc-
ible by IFNγ in HCT116 cells (Fig 2E). NLRP3 was expressed at considerable levels only in duo-
denum, rectum and CRC samples, but not in normal ileum and colon biopsies (Fig 2F). While
the role of NLRP13 remains unclear, additional data on the reported occurrence of somatic
mutations in these genes in CRC suggest that NLRP2, NLRP3 and NLRP6 may impact CRC
development and survival via immune cells, whereas NLRP5 might be relevant in gut tissues
themselves, possibly experiencing a re-expression after malignant transformation.
Table 2. (Continued)
Gene Overall Survival (pM = 0&1) Overall Survival (pM = 0) Event-free Survival (pM = 0)
SNP Genotype Cases Death (%) HR (95%CI) p-val Cases Deaths (%) HR (95%CI) p-val Cases Events (%) HR (95%CI) p-val
1105:
Q<>K
A/A 27 11 (40.74) 0.99 (0.53–
1.86)
0.98 23 8 (34.78) 1.13 (0.53–
2.41)
0.75 23 10 (43.48) 1.04 (0.53–
2.04)
0.92
A/C + A/A 176 76 (43.18) 0.89 (0.66–
1.20)
0.44 136 41 (30.15) 0.77 (0.51–
1.17)
0.22 136 47 (34.56) 0.67 (0.46–
0.99)
0.04
NLRC5 C/C 282 128
(45.39)
1 204 64 (31.37) 1 204 73 (35.78) 1
rs74439742 C/T 75 43 (57.33) 1.42 (1.00–
2.00)
0.05 56 26 (46.43) 1.67 (1.05–
2.65)
0.03 56 31 (55.36) 1.63 (1.06–
2.49)
0.03
191: P<>L T/T 10 7 (70.00) 2.39 (1.10–
5.19)
0.03 7 4 (57.14) 3.07 (1.07–
8.80)
0.04 7 4 (57.14) 2.71 (0.96–
7.67)
0.06
C/T + T/T 85 50 (58.82) 1.50 (1.08–
2.09)
0.02 63 30 (47.62) 1.77 (1.13–
2.75)
0.01 63 35 (55.56) 1.70 (1.13–
2.57)
0.01
No. of 0–5 97 34 (35.05) 1 - 75 15 (20.00) 1 - 75 16 (21.33) 1 -
risk alleles 6–7 110 52 (47.27) 1.43 (0.92–
2.21)
0.11 79 26 (32.91) 1.53 (0.81–
2.90)
0.19 79 32 (40.51) 2.06 (1.12–
3.77)
0.02
8–12 108 62 (57.41) 1.88 (1.23–
2.86)
0.003 75 33 (44.00) 2.89 (1.55–
5.37)
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Fig 2. Expression of selected CRC-associated NLRs in immune cells, primary tissue samples or CRC cell lines.
mRNA expression of NLRP2 (A,B), NLRP5 (C), NLRP13 (D), NLRC5 (E) and NLRP3 (F) was determined relative to
the housekeeper TBP by performing triplicate (means +SD show) qPCR using TaqMan gene-specific primers and
probes on the indicated samples (see Methods). In the case of (E) HCT cells were treated with 1000 U/ml IFNγ or 50
ng/ml S. typhimurium Flagellin for 3 or 6 hours as indicated. TBP-relative ΔCt values were normalized to a reference
sample (labelled R, ΔΔCt method). N denotes samples in which no expression was detectable above Ct within 40 cycles.
https://doi.org/10.1371/journal.pone.0199350.g002
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Discussion
In the discovery set from the Czech Republic, five of 39 successfully tested SNPs were as-
sociated with CRC risk, and eight with CRC survival. An additive effect on CRC risk and sur-
vival was detected, resulting in a 2-fold increased risk and a 3-fold worse survival for carriers
of6 and8 risk alleles, respectively. Despite these promising results in the Czech popula-
tion, these associations could not be confirmed in the two large German and Scottish GWAS
data sets.
This was surprising taking into account the in silico predictions about the functionality of
the SNPs and the results of the expression analysis which showed that the genes NLRP2,
NLRP3 and NLRP6 may impact CRC development via immune cells. Accordingly, differential
expression of these genes may cause alterations in pathways providing the emerging hallmarks
of cancer, such as evading immune clearance and tumor-promoting inflammatory responses
[33]. For NLRC5, whose expression was induced in HCT116 cells by IFNγ (Fig 2E), one plausi-
ble functional outcome may be the modulation of MHC class I expression [34]. The latter
strongly correlates with CRC survival due to its effect on CD8 cytotoxic T cell and natural
killer cell immuno-surveillance [35]. According to murine data, the NLRP12 may also affect T
cell function in the context of human CRC [36]. Most intriguingly, expression of develop-
ment-related NLRP5 was undetectable in normal gut-related tissues but was up-regulated in
malignant gut tissue and colon cancer cell lines (cf. Fig 2C and Figure A in S1 File.), suggesting
for the first time a potential novel role beyond developmental control for this enigmatic NLR
in humans [8]. During oogenesis, murine Nlrp5 appears to influence mitochondrial localiza-
tion and activity, ATP content and Ca2+ homeostasis–processes which all have been linked to
NLRP3 inflammasome activation and thus inflammation in differentiated cells. NLRP5 may
thus act in concert with NLRP3, which is known to be associated with human CRC [14], a
speculation warranting further investigation. The concerted association of genes of the NLR
family may directly link environmental risk factors, intestinal inflammation, the microbiota
and well-described cancer pathways involved in CRC development, such as the MAPK path-
way and the NF-κB pathway.
One might argue that the failure to replicate the association results in the Czech discovery
set might be due to differences in the clinical composition between the case-control popula-
tions of the discovery set and the replication sets (Table B in S2 File). However, data was
adjusted for all significantly different parameters except tumor location (colon or rectum; not
possible due to incomplete data) suggesting that the detected associations in the discovery set
were false positive results. In the light of the supporting gene expression data it is possible that
the coding variants analyzed in this study do actually not have an effect on the functionality of
the receptor proteins. This assumption is supported by the fact that the majority of variants are
not located in evolutionary conserved regions of the genes which allow for natural variability.
Further, it is also possible that undetected environmental factors might have biased the results.
Especially for immune related genetic variants, interactions with environmental factors or
treatment might play a major role enhancing or even enabling effects of SNPs on CRC risk or
survival. Based on the interesting expression results, future studies of these genes and their
encoded receptors, including the analysis of regulatory genetic variants affecting the gene
expression as well as the analysis of the patient specific tumor microenvironment and tumor
infiltrating immune cells and immune constitution, may contribute to uncover the still poorly
understood role of NLRs within the intestinal immune system, as well as, in CRC development
and survival [37]. The integration of different exogenous, endogenous, tumour and immune
factors, potentially including the variants in NLR genes studied here, holds promise for future
approaches in precision medicine [37].
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Supporting information
S1 File. (Figure A) mRNA expression of NLRP5 (MATER) in CRC.
(DOCX)
S2 File. (Table A) Complete list of genotyped SNPs in candidate genes, with information
about all linked missense SNPs (r2 0.8) and the location in protein domains. NMD: non-
sense mediated decay;  Variant Effect Predictor by Ensembl http://www.ensembl.org/Homo_
sapiens/Tools/VEP (Table B) Population Description. a Z statistics: Wilcoxon Rank-Sum-Test;
b Chi-square; event = recurrence, metastasis, death. (Table C) Genotype distribution of all ana-
lysed SNPs in the Czech case-control population: Risk and Survival analysis. CRC Risk: Data
adjusted for age of diagnosis and sex. Overall Survival and Event free Survival: Data adjusted
for age of diagnosis and sex, grade and stage. Nominal significance at p 0.05; significance
level corrected for multiple testing at p 0.001. (Table D) mRNA Expression for the most
promising candidate genes: Study data and reported somatic mutations for CRC-associated
NLRs. (Table E) CRC risk and Overall survival pM0: Comparison of the SNPs with p 0.05 in
the Czech discovery set with GWAS results from the Scottish and DACHS replication sets.
Amino acid changes are given as &lt;&gt; with the amino acid position indicated. Nominal sig-
nificance at p 0.05.
(DOCX)
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